A Study of LY3819469 in Participants With Elevated Lipoprotein(a) [Lp(a)]
Completed · Phase 2 · NCT05565742
Conditions: Lipoprotein Disorder
At a glance
- Research payments reported, 2025
- $159,519
- U.S. investigators named
- 9
- Sites paid
- 5
- Planned or actual enrollment
- 320
About the trial
- Sponsor
- Eli Lilly and Company
- Tested
- LY3819469 (drug), Placebo (drug)
- Dates
- Started 2022-10-20; completion 2024-10-17
- Results posted
- Yes
The main purpose of this study is to determine the efficacy and safety of LY3819469 in adults with elevated lipoprotein(a). The study will lasts about 20 months.
From ClinicalTrials.gov, last updated 2025-05-28. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Eli Lilly and Company reported $159,519 in research payments for this study in 2025 (10 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Jitendra Sharma, M.B.B.S Neurology · Birmingham, AL
- Gigi C. Lefebvre, MD Family Medicine · St Petersburg, FL
- Jason R. Morris, MD Family Medicine · Lake Charles, LA
- Peta-gay Jackson-booth, M.D. Internal Medicine · Baltimore, MD
- Agam Bansal, MD Internal Medicine · Cleveland, OH
- Sridhar Guduri, M.D Allergy & Immunology · Dublin, OH
- Marjan U. Mujib, MD, MPH Cardiology · Lancaster, PA
- Venkatesh K. Nadar, MD Cardiology · Camp Hill, PA
- Ali M. Bajwa, M.D. Family Medicine · Houston, TX
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Care Access Research LLC $130,146
- Capital Area Research LLC $11,500
- Cleveland Clinic, OH $7,638
- Cr Services Acquisition US LLC $6,435
- Lancaster General Hospital, PA $3,800
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.